Trade AnaptysBio - ANAB CFD

46.65-1.31%
The chart shows the ANAB stock price data over the last 1 day, with a current price of 46.93, a high of 47.45, and a low of 45.96.
Low: 45.96High: 47.45
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.28
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02226 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.01)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00004%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close47.27
Open45.96
1-Year Change24.52%
Day's Range45.96 - 47.45

Trade AnaptysBio - ANAB

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).

Latest shares articles

Take-Two heads into GTA VI launch with a weaker quarter and full-year outlook unchanged
Take-Two’s Q2 Net Bookings came in below guidance, but GTA VI pre-orders are at ‘unprecedented levels’. What the launch could mean for TTWO stock.
13:30, 19 November 2026
Nvidia stock forecast: Third-party price target
NVIDIA stock forecast: Q3 earnings, CEO transition
US semiconductor giant NVIDIA (NVDA) reported third-quarter fiscal 2027 revenue of $115.8bn on 17 November 2026, up 103% year on year. Explore third-party price targets and technical analysis. Past performance isn't a reliable indicator of future results.
13:40, 18 November 2026
Nvidia results preview: what to expect from Q3 after the AI sell-off
Revenue guidance of USD 108bn, a new interim CEO and an AI sell-off: what investors are watching as Nvidia reports its fiscal Q3 2027 results.
12:06, 17 November 2026
What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026

User feedback and ratings

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready